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Carbon-11 (llC)-palmitate is chemically identical to its physiological counterpart. After intravenous injection
the myocardial distribution of nC-activity can be measured accurately by positron emission tomography.
Regions of decreased ' ' C-palmitate uptake can be readily identified and their size quantified. Results obtained in
dogs with experimental coronary thrombosis and in patients with myocardial infarction indicate that positron
emission tomography with "C-palmitate allows non-invasive assessment of the metabolic recovery of the
myocardium after lysis of the occluding coronary thrombus.
There is experimental evidence that the rate of clearance of " C-palmitate activity from the myocardium is
related to oxidative fatty acid metabolism. In dogs, a restriction of the oxygen supply to the myocardium results
in a decrease in the rate of llC-clearance independently of whether myocardial perfusion is concomitantly
reduced or not.
Similarities in myocardial uptake and clearance exist between iodine-123 (l2iI)-heptadecanoic acid and " C -
palmitate. However, interpretation of the kinetics of the radio-iodinated fatty acid analogue has to take into
account the different intracellular fate of the iodine label compared with the fatty acid structure.
Efforts to 'metabolically image' the myocardium
with labelled fatty acids were first suggested by
Evans et a/.(1). The growing interest in imaging
radio-iodinated fatty acid analogues over the past
few years has closely paralleled the development of
positron emission tomography (PET)(2~5). The
introduction of cyclotron produced carbon-11 ("C;
half-life 20-4 min) into biomedical research per-
mitted for the first time the ability to label metabolic
substrates such as palmitate with an isotope which is
detectable externally, and which does not alter the
biochemical behaviour of the molecule. The physio-
logical properties of "C-palmitate together with the
imaging characteristics of PET have provided a
promising approach for non-invasive assessment of
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regional myocardial fatty acid metabolism in
patients'2 '4-6-'2 ' .
The hypothesis underlying this approach is that
metabolic alterations are reflected in modifications
of externally detectable uptake and clearance of
radioactivity of "C-palmitate by the myocardium. It
is obvious that factors other than oxidative
metabolism, including tracer supply, circulating
metabolites and washout of labelled molecules, may
also influence the time course of myocardial
radioactivity. Therefore "C-palmitate has been
studied in experimental animals aimed at defining
the interrelations between myocardiaj fatty acid
metabolism and externally detectable tracer kinetics.
The following discussion of "C-palmitate is
intended (1) to provide a review of experimental
findings, (2) to summarize clinical applications and
(3) to provide a comparison with studies employing
iodine-123 (I23I)-heptadecanoic acid.
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Positron emission tomography versus single photon
imaging
Positron emission tomography takes advantage of
the decay characteristics of this class of isotopes:
each positron 'annihilates' with an electron in close
vicinity to the nuclear decay. As a result of this
interaction two gamma photons are emitted in
diametrically opposed directions. Recording of
coincidence events (i.e. the detection of gamma
photons at nearly the same instant) by multiple pairs
of opposed detectors arranged around the chest
permits reconstruction of the distribution of activity
within the body in tomographic cross-sections.
Sequential tomographic imaging allows analysis of
tracer kinetics in well defined regions of interest
without distortion by tracer in superimposed tissue,
a limitation inherent to planar imaging tech-
niques'212"15'. In addition, since the coincidence
count rate, unlike the single photon count rate, is
independent of the position of the radioactive source
between the detectors, the local tissue tracer
concentration can be measured in terms of micro-
curies per gram of tissue'2-12"15'. Difficulties in
attenuation correction represent the principal limita-
tion of quantification of tissue isotope concentration
by single photon emission tomography'15).
Routine use of PET is limited by the costs
involved in the tomographic instrument itself and in
the production of the short lived tracers requiring an
on site cyclotron'16'.
Experimental studies with ''C-palmitate
MYOCARDIAL UPTAKE
After intravenous injection in dogs, l 'C-palmitate
accumulates in normal myocardium and disappears
rapidly from blood permitting clear delineation of
the myocardium in tomographic images'8'. During
complete coronary occlusion"'12' or after produc-
tion of critical coronary narrowing followed by
atria! pacing'17', a defect in11 C-palmitate uptake is
apparent in the ischaemic region. "C-palmitate
uptake is determined by the arterial input function,
myocardial perfusion and the extraction fraction.
Since the arterial tracer concentration is identical for
the entire myocardium, the latter two factors have to
be considered to explain the regional differences
noted in "C-palmitate uptake during ischaemia. It is
obvious that myocardial blood flow and hence tracer
supply is reduced in ischaemic compared with
normal myocardium. However, in the same region,
myocardial work and oxidative metabolism, two
major determinants of fatty acid uptake, are reduced
concomitantly'18'. In isolated perfused rabbit hearts
maintained at a constant work load and oxygen
consumption, the extraction fraction of 14C-
palmitate is inversely related to flow resulting in
constant net uptake over a flow range between 0-5
and 1-5 ml min"1 g~1(19). However, at a given flow
rate uptake is increased if work load is augmented.
Thus, the myocardial distribution of activity after
administration of l 'C-palmitate does likely not
primarily reflect myocardial perfusion, but rather
delineates zones of altered fatty acid uptake
independent of whether flow is altered.
Because of the capability of PET to accurately
quantify the size of uptake defects'20' and the
dependence of myocardial n C-palmitate uptake on
metabolic activity, this approach is promising for the
non-invasive assessment of the extent of myocardial
salvage achieved by reperfusion of ischaemic
regions'21'. In a dog model of coronary thrombosis
intracoronary streptokinase infusion resulted in a
marked increase of n C-palmitate uptake in the
region of the previous defect if perfusion was re-
established between 1 and 2 hours after occlusion
(Fig. 1)<9). Recovery of nC-palmitate uptake was
progressively attenuated with prolongation of occlu-
sion and was virtually absent if reperfusion was
instituted later than 6 h after occlusion despite an
average recovery of myocardial perfusion to 65% of
normal'9'22'. The time course of the development of
irreversible depression of ' 'C-palmitate uptake is
similar to the progression of irreversible damage
determined by histochemical criteria'23'. Neverthe-
less, "C-palmitate may underestimate the mass of
viable myocardium since enhanced accumulation of
18F-2-fluoro-2-deoxyglucose and nC-glucose has
been observed in some regions of depressed n C-
palmitate uptake'2'3'.
CLEARANCE OF MYOCARDIAL ACTIVITY
In dogs clearance of ' 'C-palmitate remaining in
the myocardium after the initial vascular transit
typically exhibits a biexponential pattern with an
early rapid phase between 5 and 10 min and a slow
phase, evident later than 20 min after tracer injection
(Fig. 2)'8-24'25'. This behaviour is compatible with
incorporation of tracer into at least two different
lipid compartments'26'. In normal myocardium more
than 90% of activity appearing during the early
rapid component in the coronary venous blood is in
form of nCO2(27). Furthermore in the fasting state,
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Figure I Midventricular transverse positron emission tomograms of a dog heart after
intravenous injection of "C-palmitate. The images on the left hand side were obtained 1-5 h after
occlusion of the left anterior descending coronary artery by an experimentally induced thrombus.
There exists a large uptake defect in the anterior wall (arrow). Streptokinase was then infused
intracoronarily and a second "C-palmitate injection followed by a second tomogram performed
one and a half hours after thrombolysis (images on the right). After reperfusion the defect fills in
substantially indicating myocardial salvage (from Bergmann el al., Am J Med 1983; 73: 573-81.
Reproduced with permission).
the fraction of extracted activity released as U C O 2 is
closely related to myocardial oxygen consump-
tion(25427). Therefore oxidative metabolism is respon-
sible for the bulk of clearance of activity from the
normal myocardium.
The effect of ischaemia on myocardial
time-activity curves was assessed in open chest dogs
with controlled perfusion of a coronary artery and
continuous monitoring of myocardial activity by a
positron detector after intracoronary "C-palmitate
injection'2*'. After reduction of myocardial perfusion
by 76%, sufficient to induce lactic acid production,
the slope of "C-clearance during the interval of the
early component was consistently decreased com-
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pared to control conditions'24'. A reduction of early
"C-clearance of similar magnitude was observed
when oxygen supply was restricted to a comparable
extent at normal flow by hypoxic perfusion
(Fig. 2)(24). Therefore decreased washout of labelled
metabolic products appears not to be primarily
responsible for the decreased clearance of activity
from "C-palmitate during ischaemia. Decreased
release of myocardial activity is mostly compatible
with impairment of fatty acid oxidation and
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Figure 2 Semilogarithmic plots of regional time-activity
curves obtained with a positron detector in an open chest
dog with controlled perfusion of the left anterior
descending coronary artery by an extracorporeal circuit.
Under control conditions (top panel) clearance of
myocardial activity exhibits three components: (1) vascular
transit of non-extracted tracer; (2) early rapid myccardial
phase evident between 5 and 10 min after injection; (3) late
slow phase of clearance. During perfusion at normal flow
rate with venous blood (bottom panel) exhibiting a
haemoglobin saturation with oxygen (SOJ) of 30% the rate
of early monoexponential "C-clearance is markedly
decreased indicating impaired fatty acid oxidation.
MBF = myocardial blood flow; t^  = half-time of rapid
early monoexponential clearance; k = rate constant of
clearance (from Lerch el al., Circulation 1982; 65: 731-8).
lipids such a triglycerides'26'. Further evidence for
the predominant role of oxidative metabolism for
nC-clearance has been provided by dog experiments
demonstrating decreased clearance of activity during
demand induced ischaemia at unaltered perfusion'171
and during suppression of fatty acid oxidation by
infusion of glucose and insulin'28'. Thus, reduced
fatty acid oxidation is reflected in reduction of the
externally detectable clearance of activity from ' 'C-
palmitate. However, limitations for quantification of
fatty acid oxidation in absolute terms from
time-activity curves include variable back-diffusion
of non-metabolized fatty acids which becomes
prominent during ischaemia and hypoxia'27'.
Patient studies with '' C-palmitate
PET with "C-palmitate has permitted detection
of infarcted regions in patients with recent or remote
myocardial infarction'410-"'. In the case of electro-
cardiographically defined non-transmural infarction
the sensitivity of PET is considerably higher than
conventional scintigraphy with thallium-201 in the
same patients'10'. Tomographic defect size correlated
closely with infarct size estimated from serial plasma
MB-CK. determinations'"'. Among infarct patients
undergoing "C-palmitate studies before and after
administration of a thrombolytic agent, defect size
decreased significantly in the group with successful
myocardial reperfusion but remained unchanged in
the group without thrombolysis'6'. Finally, inhomo-
geneous "C-palmitate uptake has been observed in
patients with dilated cardiomyopath/7 ' .
Recently developed positron emission tomo-
graphic devices for cardiac studies in patients permit
scanning times short enough for the determination
of myocardial "C-palmitate time-activity curves in
human hearts'29'. Initial results indicate that clear-
ance of myocardial activity is biexponential as
previously observed in dogs'29-301. In addition, the
rate of early clearance decreases markedly after
glucose administration'30' which in view of the
previous dog experiments is most likely an expres-
sion of decreased fatty acid oxidation.
123I-beptadecanoic acid and "C-palmitate
SIMILARITIES
Among several radiohalogenated fatty acid
analogues, 123I-heptadecanoic acid has initially been
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selected for clinical investigation becausejpf similar
uptake and clearance of activity compared to ' 'C-
palmitate in the myocardium of mice'31'. Studies in
patients employing scintigraphy or limited angle
tomography show clear visualization of the left
ventricle 5 minutes after intravenous injection of
123I-heptadecanoic acid'32"33 ' . Zones of infarction
are readily detectable (32t 35). Clearance of myocardial
activity has been reported to exhibit a biexponential
pattern*3" with a half-time of the early phase'331 that
closely agrees to the one observed in patients studied
with ''C-palmitate'30 '. The slope of the early
component was decreased during stress in regions
corresponding to stenosed coronary arteries in
patients with ischaemic heart disease'33' and in
normal myocardium after glucose/insulin infu-
sion'35'. Furthermore, inhomogeneous uptake and
clearance of activity from I23I-heptadecanoic acid
has been observed in patients with dilated cardio-
myopathy136'. These findings are very similar to
those obtained in comparable studies with " C -
palmitate despite the intrinsic differences in the
radiopharmaceuticals used as well as in the imaging
methods. Other observations with 123I-heptadeca-
noic acid include delayed clearance of activity at rest
in patients with coronary artery disease'33' and
increased rate of clearance in regions of myocardial
infarction'32'. Furthermore, in dogs, the rate of
clearance was decreased during beta blockade'37'
and after administration of toxic doses of doxo-
rubicin'38'. Studies with nC-palmitate comparable
to these latter investigations have not been published
so far.
THE DIFFERENCE
Because of the similarity of myocardial uptake
and clearance of activity between 123I-heptadecanoic
acid and "C-palmitate, it is tempting to speculate
that the kinetics of both tracers are dominated by
identical physiological, metabolic processes. Never-
theless, in contrast to "C-palmitate, 123I-heptadeca-
noic acid is not a natural substrate of fatty acid
metabolism. Therefore differences in the chemical
and physical properties of iodinated intermediates or
end products of metabolism compared with their
physiological counterparts may modify the response
to metabolic alterations and findings between the
two tracers cannot directly be related.
For example, production of iodide-123 released
into the coronary circulation from extracted
123I-heptadecanoic acid may respond differently to
metabolic alterations than formation " C O 2 from
"C-palmitatc. Deiodination independent. of-meta-
bolic degradation of the fatty acid structure has been
suggested by some authors based on observations
with structurally modified terminally iodinated fatty
acid analogues which are not substrates for beta-
oxidation'39'. Such non-specific deiodination would
limit the use of 123I-heptadecanoic acid to probe
oxidative fatty acid metabolism based on analysis of
myocardial clearance curves. However, in isolated
perfused rat hearts, myocardial release of iodide-123
from 123I-heptadecanoic acid was reduced to a
similar extent as 14CO2 production from 14C-
palmitate during cardioplegia or inhibition of fatty
acid oxidation by phenylalkyloxirane carboxylic acid
(POCA)'40'. Thus, deiodination of 123I-heptadeca-
noic acid appears to be related to oxidative fatty acid
metabolism.
Another factor which may preclude recognition of
variations in cellular deiodination of 123I-heptadeca-
noic acid is slow membrane transport leading to
prolonged retention of produced iodide-123 in the
myocyte. Based on several experimental studies
supporting this possibility'4'•42), it has been pro-
posed that observed alterations in myocardial 1 2 3I-
clearance reflect altered membrane properties rather
than altered fatty acid metabolism'41'43'. Neverthe-
less, the relative importances of factors potentially
modifying externally detectable myocardial kinetics
of 123I-heptadecanoic acid under conditions such as
ischaemia, which include myocardial perfusion,
metabolism and membrane integrity, remain to be
defined.
Supported by Swiss National Science Foundation grant
3.917.0.82.
References
(1) Evans JR, Gunton RW, Baker RG, Beanlands DS,
Spears JC. Use of radioiodinated fatty acids for
photoscans of the heart. Circ Res 1965; 16: 1-10.
(2) Bergmann SR, Fox KAA, Geltman EM, Sobel BE.
Positron emission tomography of the heart. Prog
Cardiovasc Dis (in press).
(3) Schelbert HR. Blood flow and substrate use in normal
and diseased myocardium, pp. 342-8. In: Phelps ME,
moderator. Positron computed tomography for studies
of myocardial and cerebral function. Ann Int Med
1983; 98: 339-59.
(4) Sobel BE, Weiss ES, Welch MJ, Siegel BA, Ter-
Pogossian MM. Detection of remote myocardial
infarction in patients with positron emission transaxial
tomography and intravenous "C-palmitate.
Circulation 1977; 55: 853-7.
26 R. A. Lerch and S. R. Bergmann
(5) Weiss ES, Hoffman EJ, Phelps ME et al. External
detection and visualization of myocardial ischemia
with "C-substrates in vitro and in vivo. Circ Res
1976; 39: 24-32.
(6) Sobel BE, Geltman EM, Tiefenbrunn AJ et al.
Improvement of regional myocardial metabolism after
coronary thrombolysis induced with tissue-type
plasminogen activator or streptokinase. Circulation
1984; 69: 983-90.
(7) Geltman EM, Smith JL, Beecher D, Ludbrook PA,
Ter-Pogossian MM, Sobel BE. Altered regional
myocardial metabolism in congestive cardiomyopathy
detected by positron emission tomography. Am J Med
1983; 74: 773-85.
(8) Lerch RA, Ambos HD, Bergmann SR, Welch MJ,
Ter-Pogossian MM, Sobel BE. Localization of viable,
ischemic myocardium by positron-emission tomo-
graphy with "C-palmitate. Circulation 1981; 64:
689-99.
(9) Bergmann SR, Lerch RA, Fox KAA el al. Temporal
dependence of beneficial effects of coronary throm-
bolysis characterized by positron tomography. Am J
Med 1982; 73: 573-81.
(10) Geltman EM, Biello D, Welch MJ, Ter-Pogossian
MM, Roberts R, Sobel BE. Characterization of non-
transmural myocardial infarction by positron-emission
tomography. Circulation 1982; 65: 747-56.
(11) Ter-Pogossian MM, Klein MS, Markham J, Roberts
R, Sobel BE. Regional assessment of myocardial
metabolic integrity in vivo by positron-emission
tomography with "C-labelled palmitate. Circulation
1980; 61: 242-55.
(12) Weiss ES, Siegel BA, Sobel BE, Welch MJ, Ter-
Pogossian MM. Evaluation of myocardial metabolism
and perfusion with positron-emitting radionuclides.
Prog Cardiovasc Dis 1977; 20: 191-206.
(13) Sobel BE, Bergmann SR. Cardiac positron emission
• tomography. Int J Cardiol 1982; 2: 273-7.
(14) Brownell GL, Budinger TF, Lauterbur PC, McGeer
PL. Positron tomography and nuclear magnetic
resonance imaging. Science 1982; 215: 619-26.
(15) Gould KL. Quantitative nuclear cardiology. Circula-
tion 1982; 66: 1141-6.
(16) Evens RG, Siegel BA, Welch MJ, Ter-Pogossian MM.
Cost analysis of positron emission tomography for
clinical use. Am J Radiol 1983; 141: 1073-6.
(17) Schelbert HR, Henze E, Keen R el al. C-ll palmitate
for the noninvasive evaluation of regional myocardial
fatty acid metabolism with positron computed tomo-
graphy. IV. In vivo evaluation of acute demand-
induced ischemia in dogs. Am Heart J 1983; 106:
736-50.
(18) Neely JR, Rovetto MJ, Whitmer JT, Morgan HE.
Effects of ischemia on function and metabolism of
the isolated working rat heart. Am J Physiol 1973; 225:
651-8.
(19) Fox KAA Nomura H, Sobel BE, Bergmann SR.
Persistent substrate utilization despite reduced flow in
hearts with maintained work. Am J Physiol 1983; 244:
H799-806.
(20) Weiss ES, Ahmed SA, Welch MJ, Williamson JR, Ter-
Pogossian MM, Sobel BE. Quantification of infarction
in cross-sections of canine myocardium in vivo with
positron emission transaxial tomography and "C-
palmitate. Circulation 1977; 55: 66-73.
(21) Rentrop P, Blanke H, Karsch KR, Kaiser H,
Kostering H, Leitz K. Selective intracoronary throm-
bolysis in acute myocardial infarction and unstable
angina pectoris. Circulation 1981; 63: 307-17.
(22) Bergmann SR, Fox KAA, Rand AL, Welch MJ, Ter-
Pogossian MM, Sobel BE. Assessment of restoration
of myocardial perfusion and metabolism with positron
emission tomography after coronary thrombolysis. J
Nucl Med 1983; 24: 5 (Abstr).
(23) Jennings RB, Reimer KA. Factors involved in
salvaging ischemic myocardium: effect of reperfusion
of arterial blood. Circulation 1983; 68 (Suppl I):
1-25-36.
(24) Lerch RA, Bergmann SR, Ambos HD, Welch MJ,
Ter-Pogossian MM, Sobel BE. Effect of flow-
independent reduction of metabolism on regional
myocardial clearance of "C-palmitate. Circulation
1982; 65: 731-8.
(25) Schon HR, Schelbert HR, Robinson G el al. C-ll
labeled palmitic acid for the noninvasive evaluation of
regional myocardial fatty acid metabolism with
positron-computed tomography. I. Kinetics of C-ll
palmitic acid in normal myocardium. Am Heart J
1982; 103: 532-17.
(26) Scheurer J, Brachfeld N. Myocardial uptake and
fractional distribution of palmitate-1-'*C by the
ischemic dog heart. Metabolism 1966; 15: 945-54.
(27) Fox KAA, Ambos D, Nomura H, Bergmann SR,
Sobel BE. The importance of back-diffusion on
myocardial kinetics of "C-palmitate. J Am Coll Card
1984; 3! 574 (Abstr).
(28) Schelbert HR, Henze E, Schon HR et al. C-ll
palmitate for the noninvasive evaluation of regional
myocardial fatty acid metabolism with positron
computed tomography. III. In vivo demonstration of
the effects of substrate availability on myocardial
metabolism. Am Heart J 1983; 105: 492-504.
(29) Geltman EM, Bergmann SR, Eisenberg JE, Ter-
Pogossian MM, Sobel BE. Quantitative assessment of
regional myocardial perfusion and metabolism in
patients with time-of-flight positron emission tomo-
graphy. J Am Coll Card 1984; 3: 173 (Abstr).
(30) Henze E, Grossman RG, Huang SC, Barrio JR,
Phelps ME, Schelbert HR. Myocardial uptake and
clearance of C-ll palmitic acid in man: effects of
substrate availability and cardiac work. J Nucl Med
1982; 23: 12 (Abstr).
(31)Machulla HJ, Stocklin G, Kupfernagel C et al.
Comparative evaluation of fatty acids labeled with C-
11, Cl-34m, Br-77, and 1-123 for metabolic studies of
the myocardium: concise communication. J Nucl Med
1978; 19: 298-302.
(32) Van der Wall EE, den Hollander W, Heidendal GAK,
Westera G, Majid PA, Roos JP. Dynamic myocardial
scintigraphy with 123I-labeled free fatty acids in
patients with myocardial infarction. Eur J Nucl Med
1981; 6: 383-9.
(33) Van der Wall EE, Heidendal GAK, den Hollander W,
Westera G, Roos JP. Metabolic myocardial imaging
with ' "1-labeled heptadecanoic acid in patients with
angina pectoris. Eur J Nucl Med 1981: 6: 391-6.
Myocardial metabolism with llC-palmiiate 27
(34) Roesler H, Hess T, Weiss M et al. Tomoscintigraphic
assessment of myocardial metabolic heterogenity. J
Nucl Med 1983; 24: 285-96.
(35) Dudczak R. Myokardszintigraphie mit Jod-123-
markierten Fettsauren. Wien Klin Wschr 1983; 95
(Suppl 143): 3-35.
(36) Hock A, Freundlieb C, Vyska K, Ldsse B, Erbel R,
Feinendegen LE. Myocardial imaging and metabolic
studies with (17-123I) iodoheptadecanoic acid in
patients with idiopathic congestive cardiomyopathy. J
Nucl Med 1983; 24: 22-8.
(37) Comet M, Wolf JE, Pilichowski P et al. Effect of
propranolol on myocardial imaging with radio-
iodinated hexadecanoic acid in the dog heart.
Proceedings of the Third World Congress of Nuclear
Medicine and Biology 1982; 1687-9.
(38) Styles CB, Noujaim AA, Jugdutt BI el al. Effect of
doxorubicin on (a>-I-131) heptadecanoic acid myocar-
dial scintigraphy and echocardiography in dogs. J
Nucl Med 1983; 24: 1012-8.
(39) Otto CA, Brown LE, Scott AM. Radioiodinated
branched-chain fatty acids: substrates for beta oxida-
tion? concise communication. J Nucl Med 1983; 25:
75-80.
(40) Chatelain P, Luthy P, Busslinger B, Moret P,
Blauenstein P, Lerch R. Effect of reduced fatty acid
metabolism on myocardial 1-123 release from 1-123-
heptadecanoic acid. J Molec Cell Cardiol 1984; 16
(Suppl 2): 72 (Abstr).
(41) Kloster G, Stdcklin G. Determination of the rate-
determining step in halofatty acid-turnover in the
heart. In: Hofer R, Bergmann H, eds. Radioaktive
Isotope in Klinik und Forschung 1982; 15: 235-40.
(42) Visser FC, Westera G, van der Wall EE, Roos JP.
Does the turnover rate of 123I-FFA reflect cardiac
FFA metabolism? Eur Heart J 1983; 4 (Suppl E): 92
(Abstr).
(43) Smith III EF, Kloster G, Schror K, Stocklin G.
Radioiodinated a>-halofatty acid: a probe for myocar-
dial membrane integrity. J Molec Cell Cardiol 1983; 15
(Suppl 1): 289 (Abstr).
